

Electronic Acknowledgement Receipt

EFS ID:	6240412
Application Number:	10699110
International Application Number:	
Confirmation Number:	1866
Title of Invention:	Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration
First Named Inventor/Applicant Name:	Jerome B. Zeldis
Customer Number:	84802
Filer:	Robert Chang/Sandra Genua
Filer Authorized By:	Robert Chang
Attorney Docket Number:	9516-083-999
Receipt Date:	09-OCT-2009
Filing Date:	30-OCT-2003
Time Stamp:	19:12:52
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$180
RAM confirmation Number	5256
Deposit Account	503013
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		9516-083-999_IDS.pdf	71490 eb81bc3a76d0d6b0d49715db26d23ec97bc9526	yes	2
Multipart Description/PDF files in .zip description					
	Document Description		Start		End
	Transmittal Letter		1		1
	Information Disclosure Statement (IDS) Filed (SB/08)		2		2
Warnings:					
Information:					
2	Foreign Reference	TW426520.pdf	761686 2c0cd133a01447d4d4d6c57388d30f9db16059e	no	23
Warnings:					
Information:					
3	NPL Documents	Ferrara.pdf	1196576 4c4eb8c5f81686c0847a7c76db1d6b1cd5503811	no	14
Warnings:					
Information:					
4	NPL Documents	SearchReport.pdf	41145 5025a02d4bb30c0e0c7d0e8f676ef6acc2ba432b	no	1
Warnings:					
Information:					
5	Fee Worksheet (PTO-875)	fee-info.pdf	30294 67c6603f144a0c8f81ac26d28378e67285b30a6dc	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			2101191		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.